Q3 EPS Estimate for Denali Therapeutics Decreased by Analyst

Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - Investment analysts at Leerink Partnrs cut their Q3 2025 earnings per share (EPS) estimates for shares of Denali Therapeutics in a research note issued on Wednesday, May 7th. Leerink Partnrs analyst M. Goodman now anticipates that the company will post earnings of ($0.68) per share for the quarter, down from their previous estimate of ($0.66). The consensus estimate for Denali Therapeutics' current full-year earnings is ($2.71) per share. Leerink Partnrs also issued estimates for Denali Therapeutics' Q4 2025 earnings at ($0.80) EPS, FY2025 earnings at ($3.00) EPS, FY2028 earnings at $0.45 EPS and FY2029 earnings at $0.50 EPS.

Several other research firms also recently issued reports on DNLI. Deutsche Bank Aktiengesellschaft assumed coverage on Denali Therapeutics in a research note on Tuesday, February 11th. They issued a "buy" rating and a $31.00 price target for the company. Oppenheimer reduced their price target on Denali Therapeutics from $50.00 to $42.00 and set an "outperform" rating for the company in a research note on Monday, March 3rd. William Blair raised Denali Therapeutics to a "strong-buy" rating in a report on Thursday, April 24th. Bank of America cut their price objective on Denali Therapeutics from $30.00 to $28.00 and set a "buy" rating on the stock in a report on Monday, March 10th. Finally, The Goldman Sachs Group cut their price objective on Denali Therapeutics from $45.00 to $40.00 and set a "buy" rating on the stock in a report on Tuesday, January 28th. One investment analyst has rated the stock with a hold rating, fourteen have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $33.79.

Denali Therapeutics Price Performance

DNLI traded down $0.20 during trading on Monday, hitting $13.96. The stock had a trading volume of 134,021 shares, compared to its average volume of 1,091,593. The company has a 50 day moving average price of $14.13 and a 200-day moving average price of $19.74. The firm has a market cap of $2.03 billion, a price-to-earnings ratio of -5.05 and a beta of 1.49. Denali Therapeutics has a one year low of $10.57 and a one year high of $33.33.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported ($0.78) EPS for the quarter, missing the consensus estimate of ($0.71) by ($0.07). During the same period in the prior year, the company posted ($0.68) earnings per share.

Institutional Trading of Denali Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Sterling Capital Management LLC increased its position in Denali Therapeutics by 589.9% in the 4th quarter. Sterling Capital Management LLC now owns 1,773 shares of the company's stock valued at $36,000 after buying an additional 1,516 shares in the last quarter. Caitong International Asset Management Co. Ltd increased its holdings in Denali Therapeutics by 277.0% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 2,111 shares of the company's stock worth $29,000 after purchasing an additional 1,551 shares in the last quarter. BI Asset Management Fondsmaeglerselskab A S bought a new stake in Denali Therapeutics during the 1st quarter worth approximately $41,000. GF Fund Management CO. LTD. bought a new stake in Denali Therapeutics during the 4th quarter worth approximately $62,000. Finally, Point72 Hong Kong Ltd bought a new stake in Denali Therapeutics during the 4th quarter worth approximately $65,000. 92.92% of the stock is owned by institutional investors.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.